T he introduction of biological therapy with monoclonal antibodies against tumor necrosis factor alpha (i.e., anti-TNF) has dramatically changed the management of patients with Crohn's disease (CD). The efficacy of anti-TNF agents for inducing and maintaining remission has been demonstrated in a number of pivotal randomized, controlled trials. [1] [2] [3] [4] Infliximab (IFX), adalimumab (ADA), and certolizumab pegol have received regulatory approval for the treatment of patients with CD. 5 However, there is no published head-to-head comparison of the different anti-TNF agents, and indirect evidence has reported inconsistent estimates of their relative efficacy and safety, usually due to noncomparable study designs and populations. A head-to-head trial between anti-TNF agents is unlikely to ever be conducted. 6 Although randomized, controlled trials provide the strongest evidence in terms of efficacy, 7 the patients with inflammatory bowel disease (IBD) included in these trials are not always representative of the "real-world" population treated with anti-TNF agents. 8 It has been suggested that treatment persistence is a simple-to-measure proxy for a drug's long-term therapeutic benefits. In this regard, treatment persistence may be defined as "the duration of time from initiation to discontinuation of therapy." 9 Thus, persistence may be a marker of effectiveness, safety, and tolerability, and it represents an appealing alternative to randomized, controlled trial data for comparing interventions and therapies in the context of routine clinical practice. However, it should be borne in mind that treatment persistence might also be influenced by other factors, such as the availability of alternative treatments and the characteristics of the treated population.
In this context, the persistence of anti-TNF agents (mainly IFX, ADA, and etanercept) has been evaluated in several patient populations (especially those with rheumatoid arthritis [RA] ). However, these studies have reported conflicting results: some found no difference in persistence between the 3 biologics, others found that IFX was associated with greater persistence than ADA and etanercept, and yet others found that IFX was associated with poor persistence. [10] [11] [12] [13] In CD, most studies have focused on IFX, and there are few published data on treatment persistence for IFX versus ADA. No large, long-term cohort study has focused on this issue-especially with regard to second-line anti-TNF agents.
The main objective of this study was to compare the persistence rates of IFX versus ADA (as first-and second-line anti-TNF treatments) in a large, well-defined cohort of patients with IBD, namely the Nancy IBD cohort. [14] [15] [16] The secondary objectives were to (1) identify factors associated with persistence of treatment with first-and second-line anti-TNF agents, (2) estimate the anti-TNF retention rates for treatment with first-and second-line anti-TNF agents, and (3) describe the reasons for treatment withdrawal.
METHODS

Patient Selection
We performed an observational, retrospective, single-center study at Nancy University Medical Center (Nancy, France). All adult patients with CD treated with anti-TNF agents (IFX, ADA, or certolizumab pegol) and followed up at our center between June 2002 and May 2016 were eligible for inclusion. However, given that the number of patients treated with certolizumab pegol was small (n ¼ 4), only the patients who had received maintenance therapy with IFX or ADA for at least 6 months were included in the study. The main exclusion criteria were as follows: episodic treatment, less than 6 months of treatment, insufficient data, and follow-up at other centers. In patients treated sequentially with several anti-TNF agents, each course of treatment was analyzed separately. A total of 820 patients with CD were screened, and 487 having received maintenance therapy between June 2002 and September 2014 were included. The patient flow diagram is shown as Figure 1 .
The patients' medical records were reviewed for demographic information, the duration of the disease, the anatomical distribution, previous and concomitant medications, the duration of treatment with anti-TNF agents, and any history of surgery. CD was classified according to the Montreal classification. 17 Patients on maintenance therapy with IFX received 5 mg/kg intravenously every 8 weeks; if dose optimization was required, either the dosing interval was shortened to 4 or 6 weeks or the dose was increased to 10 mg/kg. ADA was administered subcutaneously at a dose of 40 mg every 2 weeks; if dose optimization was required, either the dosing interval was shortened to a week or the dose was increased to 80 mg every 2 weeks.
Concomitant or Previous Medications
We recorded data on medications taken before or on initiation of anti-TNF agents; these medications included immunosuppressive agents (azathioprine, 6-mercaptopurine, methotrexate, mofetil-mycophenolate, and cyclosporine), corticosteroids (budesonide or systemic steroids), 5-aminosalycilate, and antibiotics. Furthermore, we extracted data on the use of other treatments, such as local corticosteroids, enteral or parenteral nutrition, thalidomide, leukocyte apheresis, radiological drainage of abdominal abscesses, and investigational drugs.
Definitions
The treatment response was assessed at the last follow-up or at the end of the course of treatment with an anti-TNF agent. A complete response or remission was defined as the resolution of clinical symptoms: the absence of abdominal pain, cramping, gastrointestinal bleeding, and weight loss, the resumption of normal stool frequency, and fistula healing. A partial response was defined as a clinical improvement, albeit with the persistence of symptoms. Nonresponse was defined as the lack of a reduction in the severity of one or more of the clinical symptoms. Dose optimization of the anti-TNF agent (dose escalation or shortening of the dosing interval, as described above) and concomitant steroid use were allowed. The persistence of first-and second-line treatment with IFX and ADA was defined as the time interval between initiation and discontinuation of the anti-TNF agent. Causes of treatment withdrawal were classified as follows: very low or very high effectiveness (as judged by the physician), infection, infusion reaction, delayed hypersensitivity reaction, neoplasia, surgery, pregnancy, and "other causes of treatment interruption" (including drug-induced lupus, lack of compliance, surgery unrelated to CD, and logistic difficulties for IFX infusions). Discontinuation of anti-TNF therapy due to very high effectiveness was usually in the context of sustained deep remission, although a standardized definition of such did not exist in the earlier study periods.
Study Outcomes
The study's primary outcome was the persistence of IFX and ADA as first-and second-line anti-TNF treatments. The secondary outcomes were (1) factors associated with the persistence of first-and second-line treatments with anti-TNF agents, (2) retention rates for first-and second-line treatments with anti-TNF agents, and (3) reasons for treatment withdrawal.
Ethical Considerations
In accordance with the French legislation on retrospective trials, information about the Nancy IBD cohort has been registered with the French National Data Protection Commission (Commission Nationale de l'Informatique et des Libertés; reference: 1404720). All data were processed anonymously.
Statistical Analysis
Categorical variables were described as percentages. Continuous variables were described as the mean (SD) and the median (interquartile range, [IQR] ). Pearson's chi-square test was used to compare categorical variables, and an analysis of variance was used to compare continuous variables. A survival analysis compared the duration of treatment with the 2 anti-TNF agents. The threshold for statistical significance was set to P , 0.05 in all tests. Bivariate and multivariate Cox models were used to analyze the duration of treatment with an anti-TNF agent. Variables with a P-value ,0.1 in the bivariate analysis were included in the multivariate Cox model. In line with a recent recommendation, no other variable selection methods were applied. 18 The statistical analysis was carried out using SAS software (version 9.4; SAS Institute, Inc., Cary, NC). 
RESULTS
Baseline Characteristics of the Overall Study Population
The median duration of follow-up for the overall study population was 5.4 [range 2.98-8.49] years, accounting for 1605 person-years of follow-up. The cohort comprised 487 patients with CD having received first-line treatment with an anti-TNF agent and 134 CD patients having received second-line treatment with an anti-TNF agent. Most of the patients were women (67.9%). The mean age at diagnosis was 27.2 years, and the median time interval between disease onset and the initiation of treatment with an anti-TNF agent was 4 [IQR 1-10] years. Most of the patients had no history of surgery before initiation of first-line anti-TNF treatment (n ¼ 345; 70.8%). IFX was prescribed more frequently than ADA as a first-line anti-TNF agent, whereas the reverse was true for second-line treatment. The baseline characteristics of patients having undergone first-or second-line treatment with anti-TNF agents are summarized in tables 1 and 3, respectively.
Patients Having Received First-line Treatment with an Anti-TNF Agent (n ¼ 487)
Baseline Characteristics
IFX was prescribed as a first-line anti-TNF treatment in 351 patients (72.1%), whereas ADA was prescribed in 136 patients (27.9%) ( Table 1) .
The medications taken before the initiation of an anti-TNF agent were variously thiopurines (93 patients, 19.1%), methotrexate (21 patients, 4.3%), corticosteroids (300 patients, 61.6%), budesonide (99 patients, 20.3%), antibiotics (105 patients, 21.6%), aminosalicylates (73 patients, 15%), and "other treatments" (70 patients, 14.4%).
A total of 207 patients (42.5%) were receiving other treatments on initiation of first-line treatment with an anti-TNF agent: 60 patients (12.3%) were taking corticosteroids, 153 (31.4%) were taking thiopurines, 10 (2.1%) were taking methotrexate, and 5 were receiving enteral or parenteral nutrition (1%).
Detailed data on treatments before or on initiation of firstline treatment with an anti-TNF agent are given in Table 1 , Supplemental Digital Content 1, http://links.lww.com/IBD/B469.
Retention Rates and Reasons for Anti-TNF Withdrawal
At the last follow-up, the anti-TNF agent had been withdrawn from 204 (58.1%) and 72 (52.9%) patients in the IFX and ADA subgroups, respectively. Hence, the retention rate was 41.9% for IFX and 47.1% for ADA. The reasons for treatment withdrawal were as follows: infection in 18 patients (6.5%), neoplasia in 13 patients (4.7%), infusion reaction in 38 patients (13.7%), delayed hypersensitivity reaction in 47 patients (17.0%), pregnancy in 22 patients (7.9%), very low or very high effectiveness in 66 patients (23.9%), surgery in 43 patients (15.5%), and other causes in 28 patients (10.1%). Detailed data on reasons for treatment withdrawal are given in Table 2 , Supplemental Digital Content 2, http://links.lww.com/IBD/B470. As expected, most of the patients who stopped treatment because of an infusion reaction were in the IFX subgroup (37 of 38).
Persistence of First-line Treatment with an Anti-TNF Agent
The overall mean (SD) persistence of first-line treatment with an anti-TNF agent was 3.3 (2.9) years, with values of 3.6 (3.1) years for IFX and 2.5 (2.0) years for ADA (Fig. 2) . The difference in persistence between the IFX and ADA subgroups was not statistically significant (P ¼ 0.219).
Factors Associated with Persistence
In a bivariate Cox model, the following factors were found to influence the persistence of first-line treatment with an anti-TNF agent: female sex (P , 0.0001), stricturing behavior (B2; P ¼ 0.024), previous or concomitant corticosteroid treatment (P ¼ 0.003 and P ¼ 0.042, respectively), previous thiopurine use (P ¼ 0.091), previous antibiotic treatment (P ¼ 0.065), previous use of other treatments (P ¼ 0.020), and concomitant methotrexate use (P ¼ 0.083). In the IFX subgroup, these factors were female sex (P , 0.0001), penetrating behavior (B3; P ¼ 0.012), body mass index $23.4 (P ¼ 0.08), previous corticosteroid (P ¼ 0.055) or thiopurine (P ¼ 0.056) use, and concomitant corticosteroid treatment (P ¼ 0.067). Given that all patients treated before 2009 received IFX, we evaluated the prescription date of IFX as possible factor associated with persistence. The prescription date (before versus after January 1, 2009) did not affect the persistence of first-line IFX treatment (hazard ratio [95% confidential interval] ¼ 1.2 [0.9-1.6]; P ¼ 0.27).
In the ADA subgroup, the associated factors were age under 25.4 on initiation of the anti-TNF agent (P ¼ 0.002), previous CD-related surgery (P ¼ 0.10), disease duration (P ¼ 0.095), and previous corticosteroid treatment (P ¼ 0.01).
After a multivariate Cox analysis (Table 2 ), female sex (P ¼ 0.0005) and stricturing behavior (B2; P ¼ 0.008) were associated with poor persistence of first-line anti-TNF treatment. In the IFX subgroup, female sex (P ¼ 0.0005) and body mass index $23.4 (P ¼ 0.034) were associated with lower persistence. We did not identify any factors significantly associated with persistence in the ADA subgroup.
Patients Having Received Second-line Treatment with an Anti-TNF Agent (n ¼ 134)
Baseline Characteristics
A total of 115 patients received second-line treatment with ADA (85.8%), and 19 patients were treated with IFX (14.2%) ( Table 3 ). The median age on initiation of second-line treatment with an anti-TNF agent was 29.3 [IQR 25-41] years. The mean duration of CD was 9.1 (SD 6.7) years. The disease duration was longer in the ADA subgroup than in the IFX subgroup (9.5 versus 6.6 yrs, respectively), although the difference was not statistically significant (P ¼ 0.084). Forty-three patients (32.1%) had history of CD-related surgery before initiation of the second-line treatment with an anti-TNF agent. Thirty-eight (28.4%) patients were taking other medications on initiation of the second-line anti-TNF treatment, 16 patients (11.9%) were on corticosteroids, 21 (15.7%) were on thiopurines, 7 (5.2%) were on methotrexate, and 4 patients received enteral nutrition.
Data on treatments received before and on initiation of second-line treatment with an anti-TNF agent are summarized in 
Retention Rates and Reasons for Anti-TNF Withdrawal
At the last follow-up, the anti-TNF agent had been withdrawn from 12 (63.1%) and 68 (59.1%) patients in the IFX and ADA subgroups, respectively. Hence, the retention rate was 36.9% for IFX and 40.9% for ADA. Reasons for therapy withdrawal were as follows: surgery in 18 patients (22.5%), infection in 6 patients (7.5%), neoplasia in 2 patients (2.5%), infusion reaction in 5 patients (6.3%), delayed hypersensitivity reaction in 11 patients (13.8%), pregnancy in 2 patients (2.5%), very low or very high effectiveness in 29 patients (36.3%), and other reasons in 7 patients (8.7%). Detailed data on reasons for withdrawal are given in Table 4 , Supplemental Digital Content 4, http://links.lww.com/IBD/B472.
Persistence of Second-line Treatment with an Anti-TNF Agent
The overall mean (SD) persistence of second-line treatment with an anti-TNF agent was 2.5 (2.1) years (Fig. 3) , with values of 2.2 (1.9) years for IFX and 2.6 (2.1) years for ADA. The difference in persistence between the IFX and ADA subgroups was not statistically significant (P ¼ 0.48).
Factors Associated with Persistence
In a bivariate Cox model analysis, age under 37.2 (P ¼ 0.016) was associated with poor persistence of anti-TNF treatment. In the ADA subgroup, the presence of a concomitant enteral or parenteral nutrition was associated with lower persistence (P ¼ 0.007). In the IFX subgroup, we did not find any factors associated with persistence. In a multivariate Cox model, the only factor associated with lower overall persistence of second-line treatment with an anti-TNF agent was age under 37.2 years (P ¼ 0.005). In the ADA subgroup, age under 37.2 years (P ¼ 0.025) and presence of a concomitant enteral or parenteral nutrition (P ¼ 0.007) were associated with lower persistence. In the IFX subgroup, we did not find any factors associated with persistence (Table 4) .
DISCUSSION
This study of a large cohort of patients with CD focused on the persistence of IFX versus ADA in routine clinical practice. The study's primary objective was to define and compare the persistence of treatments with IFX and ADA. In this regard, we did not observe a significant difference between the 2 biologics (for either first-or second-line treatment). When considering pooled data for the IFX and ADA subgroups, the overall mean persistence for first-and second-line treatments with an anti-TNF agent was 3.3 (SD 2.9) years and 2.5 (SD 2.1) years, respectively.
Our results add to the scarce data on the persistence of IFX and ADA in general and their use as second-line anti-TNF treatments in particular. A recent cohort study found that there was no significant difference in persistence between the 2 biologics; the overall (IFX + ADA) median persistence was 39 [ 20 However, the limited scope of the administrative database precluded an analysis of the reasons of drug withdrawal or the factors associated with persistence.
In a Norwegian cohort that included 83 patients with IBD treated with IFX or ADA (median treatment duration: 11.4 mo; median follow-up: 59 mo), 47% of the patients were still receiving an anti-TNF agent at week 52. 21 In an Italian cohort study that included 44 IFX-treated patients and 49 ADA-treated patients, maintenance treatment was ongoing in, respectively, 60% and 67% of the cases at week 54. 22 There was no intergroup difference in the steroid-free remission rates at this timepoint. 22 Nonetheless, the small number of patients in these 2 cohort studies prevents firm conclusions from being drawn.
The treatment persistence of anti-TNF agents has been extensively studied in patients with RA population. A large, retrospective cohort study of 2418 patients with RA found similar mean persistence rates at 42 weeks for first-line treatments with IFX, ADA, and etanercept (48%, 51%, and 52%, respectively). 23 The persistence rates for second-line treatment ranged from 46% to 56% (after 36 wk of follow-up for IFX and etanercept, and after 30 wk for ADA). 23 In a large registry study that included 10,396 RA patients, the retention rate of first-line treatment with an anti-TNF agent was 71% at one year but only 42% at 5 years; it was suggested that concomitant treatment with methotrexate affected the persistence of the anti-TNF agent. 24 We observed that female sex and stricturing behavior were associated with lower overall persistence for first-line treatment with an anti-TNF agent. In the IFX subgroup, female sex and a body mass index $23.4 were associated with lower persistence. By contrast, no associated factors were identified in the ADA subgroup. For second-line treatment with an anti-TNF agent, age under 37.2 was associated with lower overall persistence. In the ADA subgroup, age under 37.2 and the provision of enteral or parenteral nutrition were associated with lower persistence.
In the literature, it has been suggested that female sex is associated with lower persistence for treatment with an anti-TNF agent. 23, 25, 26 This observation may be related to sex differences in the percentage of body fat and in fat distribution. 27 The need for enteral or parenteral nutrition doubtless reflects a more severe disease course. In a subgroup analysis, no factors were associated with the persistence of first-line treatment with ADA and second line treatment with IFX; however, this might be related to the small number of patients in these subgroups and thus a lack of statistical power.
Other factors (such as concomitant treatment with thiopurines or methotrexate, the disease duration, the disease site, and a history of CD-related surgery) were not associated with the persistence of anti-TNF treatments in our study. It is noteworthy that combining ADA with an immunomodulator was associated with better treatment persistence in the study by Cosnes et al, 19 although disparities between studies are probably due to differences in data extraction and analyses. One possible explanation to this difference is the relative small percentage of patients on combination therapy on initiation of first-line anti-TNF therapy (31.4% with thiopurine and only 2.1% with methotrexate) in our cohort. What is more, unfortunately our cohort database only allowed us to extract information regarding concomitant immunosuppression on initiation of the anti-TNF agent, but could not review for how long this combination therapy with immunosuppression was withheld.
To the best of our knowledge, few other studies have formally identified predictors of the discontinuation of anti-TNF 28 More recently, Billiet et al. reported that a disease duration .1 year, L1 disease location, previous anti-TNF use, the absence of therapeutic drug monitoring, the baseline hemoglobin level, and the time until first dose optimization in the first year were independent predictors of IFX failure-free survival. 29 In this study, the main reasons for treatment withdrawal were very low or very high effectiveness, a delayed sensitivity reaction, an infusion reaction, and surgery; these findings are in line with the literature data. 28 This study had some limitations. First, it was retrospective. Second, it was carried out in a tertiary referral center, and so the study probably included an abnormally high proportion of severe cases. Third, the number of patients receiving second-line treatment with an anti-TNF agent was relatively small (although this was expected). Fourth, the patients did not undergo a systematic endoscopic assessment. Lastly, we implemented the use of therapeutic drug monitoring in 2014, and so this factor could not be analyzed in the study cohort. There were differences in the anti-TNF prescribed as first-line therapy, related to the fact that at the beginning of the studied period, only IFX had received regulatory approval for the treatment of CD. However, we compared persistence of first-line treatment with IFX between 2 periods (before and after the availability of ADA: 2002-2008 and 2009-2016), and we did not find differences in this regard. One important limitation of our study is the lack of information regarding the rate of anti-TNF optimization during follow-up between groups, which might have changed interpretation of the study results regarding drug persistence. Our study also had several strengths. This is the first study to have evaluated the persistence of IFX and ADA as both first-and second-line treatments in a large, well-defined cohort (namely the Nancy IBD cohort). We were also able to document retention rates and record all the various reasons for treatment withdrawal. Lastly, the median duration of follow-up was relatively long (5.4 yrs).
Additional long-term studies will be needed to fully understand treatment persistence in patients with CD who will probably require lifelong treatment. Higher persistence rates are associated with higher medication-related costs but lower non--medication-related costs. In particular, the costs associated with hospitalization and abdominal surgery might be reduced by high persistence. As the use of biologics becomes more frequent, increased persistence may help to avoid (1) poor outcomes, (2) the higher costs associated with treatment failure, (3) disease progression, and (4) the need for more aggressive treatments. Even though treatment persistence may be strongly influenced by a nation's healthcare system and drug access policies, it may still be considered as relevant proxy for a treatment's effectiveness and safety in routine clinical practice. Our present results suggest that IFX and ADA have similar treatment persistence rates when used as first-or second-line treatments. Treatment persistence was lower for second-line anti-TNF agents than for first-line anti-TNF agents, which probably reflects treatment-refractory disease. Knowledge of the factors associated with anti-TNF persistence may be of value in developing a personalized treatment approach for these patients.
